The current treatment for AMD therapy includes intravitreal injections of VEGF-neutralizing agents, preventing the interaction between VEGF and its receptor (VEGFR-2), since the binding triggers the endothelial cell migration and proliferation. The gene discussed is VEGFA; the disease is age-related macular degeneration.